Abstract 274P
Background
Index tumors are recognized as the most aggressive prostate tumors; however, their clinical implications remain unclear. This study aimed to investigate the occurrence of index tumor localization based on zonal origin and explore the impact of these locations on the prognosis after radical prostatectomy among patients with negative surgical margins.
Methods
In this retrospective, single-center study, a cohort of 1,109 consecutive patients who underwent radical prostatectomy was analyzed. The index tumor was defined as the largest tumor within the prostate gland. Localization was determined using McNeal's zonal origin classification on whole-mount sections. Kaplan-Meier survival curves were employed to assess biochemical recurrence (BCR)-free survival. Univariate and multivariate Cox proportional hazards analyses were conducted to identify predictive factors for early BCR (within 1 year).
Results
Among the 621 patients with negative surgical margins and no adjuvant therapy, index tumors were localized in the transitional zone in 191 patients (30.8%), the peripheral zone in 399 patients (64.3%), and the central zone in 31 patients (5.0%). A total of 22 patients (3.5%) experienced early BCR, and 70 patients (11.2%) experienced overall BCR during a median follow-up period of 61.7 months. Based on index tumor location, the early BCR-free rates were 99.5%, 95.7%, and 83.3% for the transitional, peripheral, and central zones, respectively. Multivariate analysis identified the index tumor in the central zone as an independent predictor of early BCR with negative surgical margins following radical prostatectomy, followed by the pathological grade of the prostatectomy specimen, index tumor in the peripheral zone, and a high prostate-specific antigen level.
Conclusions
This study examined the significance of index tumor location among patients with negative surgical margins after radical prostatectomy. Notably, index tumors situated in the central zone, although infrequent, emerged as the most robust predictors of early BCR. These findings may prompt urologists and patients to reconsider their therapeutic strategies for prostate cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract